Showing 1 to 2 of 2 results


Chinese Biotech Drug Outperforms Keytruda in Clinical Trials
Akeso's new lung cancer drug, Ivonescimab, outperformed Merck's Keytruda in Chinese clinical trials, extending progression-free survival; this success, coupled with increased licensing deals, highlights the rise of China's pharmaceutical innovation, though challenges in consumer trust and regulatory...
Chinese Biotech Drug Outperforms Keytruda in Clinical Trials
Akeso's new lung cancer drug, Ivonescimab, outperformed Merck's Keytruda in Chinese clinical trials, extending progression-free survival; this success, coupled with increased licensing deals, highlights the rise of China's pharmaceutical innovation, though challenges in consumer trust and regulatory...
Progress
48% Bias Score

Chinese Biotech Drug Outperforms Keytruda in Clinical Trials
Akeso, a Chinese biotech company, developed Ivonescimab, a lung cancer drug that outperformed Merck's Keytruda in clinical trials, resulting in a stock surge for its US partner and showcasing China's rising pharmaceutical innovation.

Chinese Biotech Drug Outperforms Keytruda in Clinical Trials
Akeso, a Chinese biotech company, developed Ivonescimab, a lung cancer drug that outperformed Merck's Keytruda in clinical trials, resulting in a stock surge for its US partner and showcasing China's rising pharmaceutical innovation.
Progress
40% Bias Score
Showing 1 to 2 of 2 results